1. Osteogenesis imperfecta (OI) is a genetic bone fragility disorder that can have a significant impact on patient quality of life.
2. Current treatments for OI involve antiresorptive medication, allied health, and orthopedic surgery.
3. Advances in gene editing technology and gene therapy vectors offer the potential for gene-targeted interventions to provide an enduring or permanent cure for OI.
The article provides an overview of the current state of cell and gene therapies for osteogenesis imperfecta (OI). The authors discuss emergent technologies for cell- and gene-targeted therapies, major hurdles to their implementation, and the prospects of their future success with a focus on bone disorders. The article is well written and provides a comprehensive overview of the topic.
The article is reliable in its presentation of information as it cites relevant sources such as PubMed, PMCID, DOI, etc., which adds credibility to the claims made in the article. Additionally, the authors provide detailed descriptions of current treatments for OI as well as potential advances in gene editing technology and gene therapy vectors that could potentially provide an enduring or permanent cure for OI.
The article does not appear to be biased or one-sided in its reporting; rather it presents both sides equally by providing detailed descriptions of current treatments as well as potential advances in gene editing technology and gene therapy vectors that could potentially provide an enduring or permanent cure for OI. Furthermore, the authors note possible risks associated with these treatments such as adverse effects from antiresorptive medications or potential complications from orthopedic surgery.
In conclusion, this article is reliable and trustworthy due to its comprehensive coverage of the topic at hand and its lack of bias or one-sided reporting.